Altamira Therapeutics Statistics
Total Valuation
CYTO has a market cap or net worth of $2.69 million. The enterprise value is $2.11 million.
| Market Cap | 2.69M |
| Enterprise Value | 2.11M |
Important Dates
The next estimated earnings date is Tuesday, September 10, 2024, before market open.
| Earnings Date | Sep 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYTO has 2.24 million shares outstanding. The number of shares has increased by 1,066.00% in one year.
| Shares Outstanding | 2.24M |
| Shares Change (YoY) | +1,066.00% |
| Shares Change (QoQ) | +13.79% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 0.18% |
| Float | 2.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.38 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.32 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -55.30% |
| Return on Capital (ROIC) | -90.21% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$442,900 |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.86% in the last 52 weeks. The beta is 2.43, so CYTO's price volatility has been higher than the market average.
| Beta (5Y) | 2.43 |
| 52-Week Price Change | -82.86% |
| 50-Day Moving Average | 1.36 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 42.70 |
| Average Volume (20 Days) | 280,920 |
Short Selling Information
The latest short interest is 138,204, so 6.17% of the outstanding shares have been sold short.
| Short Interest | 138,204 |
| Short Previous Month | 102,927 |
| Short % of Shares Out | 6.17% |
| Short % of Float | 6.22% |
| Short Ratio (days to cover) | 1.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.66M |
| Pretax Income | -4.36M |
| Net Income | -4.61M |
| EBITDA | -2.34M |
| EBIT | -2.48M |
| Earnings Per Share (EPS) | -$8.87 |
Balance Sheet
The company has $695,311 in cash and $112,234 in debt, giving a net cash position of $583,077 or $0.26 per share.
| Cash & Cash Equivalents | 695,311 |
| Total Debt | 112,234 |
| Net Cash | 583,077 |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 7.27M |
| Book Value Per Share | 3.25 |
| Working Capital | 376,413 |
Cash Flow
| Operating Cash Flow | -12.96M |
| Capital Expenditures | n/a |
| Free Cash Flow | -12.96M |
| FCF Per Share | -$32.60 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYTO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,066.00% |
| Shareholder Yield | -1,066.00% |
| Earnings Yield | -171.34% |
| FCF Yield | -482.22% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 13, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Dec 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |